Evaluating The Indirect Costs Of Care Associated With Salvage Chemotherapy For Relapsed And Refractory Aggressive-Histology Lymphoma: A Subset Analysis Of The Canadian Cancer Trials Group (Cctg) Ly.12 Clinical Trial
BLOOD(2017)
摘要
We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collected at baseline and with each chemotherapy cycle pre-transplant, using an adapted Lost Productivity questionnaire. Mean per patient indirect costs were CAD 2999 for patients in the GDP arm and CAD 3400 in the DHAP arm. A substantial majority was not working or had to reduce their workload during this treatment time. Salvage chemotherapy for R/R aggressive NHL is associated with significant indirect costs to patients and their caregivers.
更多查看译文
关键词
lymphoma, autologous stem cell transplantation, cost-effectiveness analysis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要